Abstract
A global outbreak of monkeypox across non-endemic regions including Europe and North America was confirmed in May 2022. The current outbreak has shown distinct epidemiological features compared with past outbreaks in non-endemic settings, most notably its observed rapid growth and predominant spread among men who have sex with men (MSM). We use a branching process transmission model fitted to empirical sexual partnership data in the UK to show that the heavy-tailed nature of the sexual partnership degree distribution, where a small fraction of individuals have disproportionately large numbers of partners, can explain the sustained growth of monkeypox cases among the MSM population despite the absence of such patterns of spread in past outbreaks. We also suggest that the basic reproduction number (R0) for monkeypox over the MSM sexual contact network may be substantially greater than 1 for a plausible range of assumptions, which poses a challenge to outbreak containment efforts. Ensuring ongoing support and tailored public health messaging to facilitate prevention and early detection among MSM with a large number of sexual partners is warranted.
Competing Interest Statement
AE received a research grant from Taisho Pharmaceutical Co., Ltd. for research outside this study.
Funding Statement
AE is supported by JSPS KAKENHI (22K17329), JSPS Overseas Research Fellowships and foundation for the Fusion Of Science and Technology. SA and SF are supported by Wellcome Trust (210758/Z/18/Z). CABP is supported by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking between European Union Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations [EBOVAC3: grant number 800176]. RR is supported by a Doctoral Foreign Study Award from the Canadian Institutes of Health Research (award number DFS-164266). EF is supported by the Medical Research Council, UKRI (MR/S020462/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The London School of Hygiene & Tropical Medicine ethics committee gave ethical approval for this work (reference number: 27985).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The underlying data is available from UK Data Service (https://ukdataservice.ac.uk) provided the End User Licence Agreement.
https://beta.ukdataservice.ac.uk/datacatalogue/series/series?id=2000036
